Coya Therapeutics (NASDAQ:COYA) Rating Lowered to Sell at Wall Street Zen

Coya Therapeutics (NASDAQ:COYA) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

A number of other equities research analysts also recently commented on COYA. Weiss Ratings restated a “sell (d-)” rating on shares of Coya Therapeutics in a research report on Wednesday, January 21st. D. Boral Capital reiterated a “buy” rating and set a $15.00 price target on shares of Coya Therapeutics in a report on Monday, March 16th. HC Wainwright reissued a “buy” rating and set a $18.00 price objective on shares of Coya Therapeutics in a research report on Monday, February 2nd. Finally, Chardan Capital restated a “buy” rating and issued a $14.00 price objective on shares of Coya Therapeutics in a report on Monday, March 16th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $16.00.

Coya Therapeutics Price Performance

Coya Therapeutics stock opened at $4.21 on Friday. The firm has a 50 day simple moving average of $4.69 and a 200-day simple moving average of $5.51. The stock has a market cap of $98.75 million, a price-to-earnings ratio of -3.31 and a beta of 0.23. Coya Therapeutics has a 1-year low of $3.94 and a 1-year high of $7.75.

Coya Therapeutics (NASDAQ:COYA) last released its quarterly earnings results on Monday, March 16th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.26). Coya Therapeutics had a negative net margin of 267.13% and a negative return on equity of 62.76%. The firm had revenue of $3.96 million for the quarter, compared to analysts’ expectations of $1.93 million. Equities analysts expect that Coya Therapeutics will post -1.15 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of COYA. Alyeska Investment Group L.P. purchased a new stake in shares of Coya Therapeutics in the 4th quarter valued at $4,640,000. AWM Investment Company Inc. purchased a new position in Coya Therapeutics during the 4th quarter valued at about $4,205,000. Private Management Group Inc. purchased a new position in Coya Therapeutics during the 4th quarter valued at about $1,626,000. Marshall Wace LLP grew its position in Coya Therapeutics by 438.8% in the 4th quarter. Marshall Wace LLP now owns 225,358 shares of the company’s stock valued at $1,307,000 after acquiring an additional 183,533 shares in the last quarter. Finally, Dauntless Investment Group LLC grew its position in Coya Therapeutics by 199.5% in the 3rd quarter. Dauntless Investment Group LLC now owns 153,021 shares of the company’s stock valued at $872,000 after acquiring an additional 101,932 shares in the last quarter. 39.75% of the stock is currently owned by hedge funds and other institutional investors.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.